Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Analysts at Wedbush lowered their Q2 2025 EPS estimates for Chimerix in a note issued to investors on Monday, December 9th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings per share of ($0.27) for the quarter, down from their prior estimate of ($0.26). Wedbush currently has a "Outperform" rating and a $6.00 target price on the stock. The consensus estimate for Chimerix's current full-year earnings is ($0.99) per share. Wedbush also issued estimates for Chimerix's Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at $0.28 EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at ($0.04) EPS.
Several other equities analysts have also recently commented on CMRX. StockNews.com raised shares of Chimerix from a "sell" rating to a "hold" rating in a research report on Wednesday, August 21st. HC Wainwright reaffirmed a "buy" rating and set a $11.00 target price on shares of Chimerix in a report on Wednesday.
Read Our Latest Stock Report on Chimerix
Chimerix Trading Up 3.0 %
CMRX stock traded up $0.09 during mid-day trading on Thursday, hitting $3.07. 5,420,714 shares of the company were exchanged, compared to its average volume of 1,244,142. The firm has a fifty day simple moving average of $0.99 and a 200 day simple moving average of $0.93. The company has a market capitalization of $276.12 million, a PE ratio of -3.40 and a beta of 1.02. Chimerix has a twelve month low of $0.75 and a twelve month high of $3.39.
Institutional Investors Weigh In On Chimerix
Institutional investors have recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock valued at $321,000 after acquiring an additional 138,098 shares during the period. Marshall Wace LLP acquired a new stake in shares of Chimerix during the 2nd quarter worth approximately $137,000. Finally, Valeo Financial Advisors LLC lifted its holdings in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 69,505 shares during the last quarter. Institutional investors own 45.42% of the company's stock.
About Chimerix
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
See Also
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
